Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Non-Current Deffered Revenue (2016 - 2020)

Karyopharm Therapeutics (KPTI) has disclosed Non-Current Deffered Revenue for 7 consecutive years, with $2.2 million as the latest value for Q1 2020.

  • For the quarter ending Q1 2020, Non-Current Deffered Revenue fell 32.45% year-over-year to $2.2 million, compared with a TTM value of $2.2 million through Mar 2020, down 32.45%, and an annual FY2019 reading of $2.2 million, down 51.63% over the prior year.
  • Non-Current Deffered Revenue was $2.2 million for Q1 2020 at Karyopharm Therapeutics, roughly flat from $2.2 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $4.5 million in Q2 2018 and bottomed at $1.4 million in Q4 2017.
  • Average Non-Current Deffered Revenue over 5 years is $2.4 million, with a median of $1.9 million recorded in 2016.
  • The sharpest move saw Non-Current Deffered Revenue skyrocketed 232.5% in 2018, then crashed 51.63% in 2019.
  • Year by year, Non-Current Deffered Revenue stood at $1.7 million in 2016, then fell by 18.19% to $1.4 million in 2017, then surged by 232.5% to $4.5 million in 2018, then plummeted by 51.63% to $2.2 million in 2019, then changed by 0.0% to $2.2 million in 2020.
  • Business Quant data shows Non-Current Deffered Revenue for KPTI at $2.2 million in Q1 2020, $2.2 million in Q4 2019, and $3.5 million in Q3 2019.